Alpha DaRT Shows Strong Pancreatic Cancer Survival, Up to 17.1 Months mOS in Heavily Pretreated Patients
DRTS has more than doubled off its 52-week low of $2.81 on elevated volume (2.7× avg).
Summary
Alpha Tau Medical reported highly positive overall survival data for its Alpha DaRT therapy in pancreatic cancer patients at the ASCO Annual Meeting. The pooled analysis showed median overall survival (mOS) of up to 17.1 months in heavily pretreated locally advanced patients and 11.2 months in metastatic patients after one line of chemotherapy, significantly outperforming historical benchmarks. This follows a series of positive clinical updates for Alpha DaRT, including earlier pooled results and an abstract presentation, and was also reported in a 6-K filing today. These strong results for a highly lethal cancer with limited treatment options are a major validation for the company's lead product. The company anticipates completing recruitment for its U.S. IMPACT pancreatic cancer trial next.
At the time of this announcement, DRTS was trading at $10.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $953.1M. The 52-week trading range was $2.81 to $11.62. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.